Telix Pharmaceuticals

ASX:TLX · AU000000TLX2

BiotechnologyMedium

360

Value47

Profit price55

EV / EBIT13

Price / Owner Earnings97

Cash yield1

Owner Earnings Yield1

Dividend Yield1

Sales & asset price34

Price/Sales45

EV / Gross Profit40

Price/Book17

Quality54

Returns on capital72

Return on Capital71

Cash Return on Capital72

Return on Equity72

Profit margins56

EBIT Margin45

Gross Profitability67

Cash backing39

Accruals16

Owner Earnings Margin61

Growth60

Sales growth58

Profit growth65

Profit Growth29

Long-Term EPS Growth100

Reinvestment62

Price momentum12

Safety13

Debt load3

Debt serviceability16

Refinancing30

Debt Payback1

Liquidity37

Sentiment54

Analyst ratings67

Expectations trend70

Opinion Changes79

Price Target Upside60

Market mood100

Value Creation6/20not creating value

Creates more value than its capital costs
Owner earnings growing
Owner earnings per share growing
Reinvests at strong returns
Solid earnings base

What this means

Telix Pharmaceuticals doesn't consistently earn more than its cost of capital, so it isn't yet creating shareholder value.

Profile

CountryAustralia

IndustryBiotechnology

SizeMedium

TypePublic Company

ExchangeASX

Founded2017

Employees604

Websitetelixpharma.com

ISINAU000000TLX2

Last UpdateApr 2, 2026

Indices

ASX 100 (Australia)ASX 200 (Australia)ASX 300 (Australia)NASDAQ (USA)

Themes

UrologyNephrologyHealth DiagnosticsHematologyPain ManagementOncologyCentral Nervous SystemBiotechnology

Description

Telix Pharmaceuticals Limited (Telix), a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic and diagnostic radiopharmaceuticals and associated medical technologies globally. The company is com…

Analysis

Middle-of-the-road

Telix Pharmaceuticals Limited is a middle-of-the-road business: neither the economics nor the price stand out from the peer group.

Valuation data is not available for this company.

The trajectory is moderate and the balance sheet is fragile. The company scores 6/20 on our value-creation score: not creating value.

What to watch: The financial cushion is thinner than comfortable. As always: this describes the company's numbers; it is not a recommendation.

360° rank · history

1007550250

2026

All-time high

Mar 2026

All-time low

Jun 2026

Average rank

across all years

Detailed & Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history.

Current202520242023

Price/Sales

—

Price/Earnings

—

Price/Book

—

Dividend Yield

—

Value (overall)

—

Cells are coloured by rank band (red weak → green strong). Sentiment & 360° history begins 2023.

Similar Stocks

The companies this stock is ranked against.

Compare Telix Pharmaceuticals with its peers

Jyong Biotech

NMQ:MENS

—

CountryTaiwan

IndustryBiotechnology

SizeSmall

Full Stock Analysis →

Wave Life Sciences

NMQ:WVE

CountrySingapore

IndustryPharmaceuticals

SizeSmall

Full Stock Analysis →

Zai Lab

HKG:9688

CountryChina

IndustryBiotechnology

SizeSmall

Full Stock Analysis →

Sinovac Biotech

NSQ:SVA

—

CountryChina

IndustryBiotechnology

SizeMedium

Full Stock Analysis →

CSL

ASX:CSL

CountryAustralia

IndustryBiotechnology

SizeX-Large

Full Stock Analysis →

Celltrion

KSC:068270

CountrySouth Korea

IndustryBiotechnology

SizeLarge

Full Stock Analysis →

Make Sense of the Ranks

Every rank runs 1–100 against true peers. Higher is always better.

360° View

1 · Watch OutGood· 100

Value

1 · ExpensiveGood Value· 100

Quality

1 · Weak FundamentalsHigh Quality· 100

Growth

1 · Tough TimesHigh Growth· 100

Safety

1 · High LeverageWell-Financed· 100

Sentiment

1 · SkepticismPositive· 100

Learn More →